One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

When I tell people I direct clinical research studies, I often encounter surprise. “Aren’t you a physician?” they ask. It ...

In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

A small but significant new study showed low doses of Ozempic helped people to drink less. Scientists are starting to ...

But if not, you'll need to find stocks that hold the potential to pack more punch. The past doesn't predict the future, but ...

Dr. Philip A. Chan joined GoLocal to discuss the new wave of weight loss drugs and their implications for fighting obesity as ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

More than 36 million Americans have type 2 diabetes, a condition primarily attributed to the body's cells not responding to ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...